Sorry, you need to enable JavaScript to visit this website.

IBRANCE (palbociclib)

Health Professional Information

SUMMARY PRODUCT INFORMATION

Route of AdministrationPharmaceutical Form/StrengthClinically Relevant Nonmedicinal Ingredients
OralCapsules 75 mg, 100 mg, 125 mgLactose monohydrate
For a complete listing see Dosage Forms, Composition and Packaging section.

Indications And Clinical Use

IBRANCE (palbociclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with:

  • an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.
  • fulvestrant in women whose disease progressed after prior endocrine therapy. Pre- or perimenopausal women must also be treated with a luteinizing hormone releasing hormone (LHRH) agonist.

Clinical effectiveness of IBRANCE in combination with an aromatase inhibitor is based on the benefit observed in patients treated with IBRANCE in combination with letrozole for the treatment of postmenopausal women with advanced breast cancer.

Geriatrics (≥ 65 years of age):
Of 444 patients who received IBRANCE in PALOMA-2, 181 (41%) patients were ≥65 years of age. Of 347 patients who received IBRANCE plus fulvestrant, 86 patients (25%) were ≥65 years of age. No overall differences in the safety and efficacy of IBRANCE were observed between these patients and younger patients in either study.  Anemia was reported more frequently in patients ≥65 than in patients <65 years of age treated with IBRANCE plus letrozole, whereas similar incidences were reported in both age groups for patients treated with IBRANCE plus fulvestrant.

Pediatrics (< 18 years of age):
Safety and efficacy of IBRANCE in children and adolescents <18 years have not been studied.

Contraindications

  • Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.

Warnings And Precautions

Serious Warnings and Precautions


IBRANCE (palbociclib) should be prescribed and managed by a qualified physician who is experienced in the use of anti-cancer agents.

The following is a significant adverse drug reaction identified in clinical trials conducted with IBRANCE:

  • Neutropenia (see Hematologic section below)

General

Effects on ability to drive and use machines
No studies of the effects of IBRANCE (palbociclib) on the ability to drive or operate machinery have been conducted. However, since fatigue and dizziness have been reported with the use of IBRANCE, patients should exercise caution when driving or operating machinery while taking IBRANCE.

Carcinogenesis and Mutagenesis

Carcinogenicity studies have not been conducted with IBRANCE.

Cardiovascular

Cardiac Electrophysiology
The effect of palbociclib in combination with letrozole on the QT interval corrected for heart rate (QTc) was evaluated using time-matched electrocardiograms (ECGs) evaluating the change from baseline in 77 patients with breast cancer from an ECG substudy of PALOMA-2.  This study suggested that palbociclib at 125 mg once daily (Schedule 3/1), when added to letrozole, had no large effect on QTc (i.e., >20 msec) (see ACTION AND CLINICAL PHARMACOLOGY).

Hematologic

Neutropenia
Neutropenia was the most frequently reported adverse reaction in patients treated with IBRANCE plus letrozole (80%) or IBRANCE plus fulvestrant (83%). Grade 3 decreased neutrophil counts were observed in approximately half of all patients, and  Grade 4 decreased neutrophil counts were observed in 5% and 11% of patients treated with IBRANCE in combination with letrozole or fulvestrant, respectively [see ADVERSE REACTIONS].

The median time to first episode of any grade neutropenia was 15 days and the median duration of Grade ≥3 neutropenia was 7 days.

Febrile neutropenia has been reported in 1.8% of patients across the IBRANCE clinical trials. One patient treated with IBRANCE plus fulvestrant died due to neutropenic sepsis.  Physicians should inform patients to promptly report any episodes of fever.

Monitor complete blood count prior to the start of IBRANCE therapy at the beginning of each cycle, as well as on Day 15 of the first 2 cycles, and as clinically indicated [see WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests]. Dose interruption, dose reduction or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia [see DOSAGE AND ADMINISTRATION]. For patients who experience Grade 3 neutropenia, consider repeating complete blood count monitoring one week later.

Other Hematologic Parameters
Decreases in leukocytes and platelets were observed in patients treated with either IBRANCE plus letrozole or IBRANCE plus fulvestrant. Grade 3 leukopenia was reported in 24% of IBRANCE plus letrozole patients and in 30% of IBRANCE plus fulvestrant patients. Decreased hemoglobin and lymphocytes were also observed in IBRANCE plus letrozole-treated patients [see ADVERSE REACTIONS].

In clinical trials with IBRANCE, anemia and leukopenia were usually managed with temporary IBRANCE discontinuation and/or dose reduction. Monitor complete blood count prior to the start of IBRANCE therapy, at the beginning of each cycle, as well as on Day 14 of the first 2 cycles, and as clinically indicated [see WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests and DOSAGE AND ADMINISTRATION].

Infections
IBRANCE may predispose patients to infections.  Infections have been more frequently reported in patients treated with IBRANCE plus letrozole (60%) and in patients treated with IBRANCE plus fulvestrant (47%) than those treated in the respective comparator arms (42% and 31%, respectively). Grade ≥3 infections occurred in 6% of patients treated with IBRANCE plus letrozole and in 3% of patients treated with letrozole alone.  Grade ≥3 infections occurred in 3% of patients treated with either IBRANCE plus fulvestrant or placebo plus fulvestrant. Monitor patients for signs and symptoms of infection and treat as medically appropriate (see WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests). Physicians should be aware of the increased risk of infection with IBRANCE and should inform patients to promptly report any episodes of fever.

Drug-Drug Interactions

CYP3A inhibitors: Concomitant use of IBRANCE and CYP3A inhibitors (e.g. clarithromycin, itraconazole, ritonavir, ketoconazole, grapefruit or grapefruit juice) may increase exposure to palbociclib. In patients receiving IBRANCE, coadministration of a strong CYP3A inhibitor should be avoided (see DRUG INTERACTIONS).

CYP3A substrates: Concomitant use of IBRANCE and a CYP3A substrate may increase exposure to the CYP3A substrate. Caution is warranted when IBRANCE is co-administered with CYP3A substrates of narrow therapeutic index, such as alfentanil, cyclosporine, dihydroergotamine, or ergotamine (see DRUG INTERACTIONS).

CYP3A inducers: Concomitant use of IBRANCE and CYP3A inducers (e.g. strong inducers such as rifampin, carbamazepine, phenytoin, St John’s Wort, and moderate inducers such as nafcillin, bosentan, modafinil) may decrease palbociclib plasma concentration. In patients receiving IBRANCE, coadministration of strong CYP3A inducers should be avoided (see DRUG INTERACTIONS).

Sexual Function/Reproduction

No clinical data have been obtained on fertility in humans. There were no effects on estrous cycle or mating and fertility in female rats in nonclinical studies. [see Special Populations]. Based on nonclinical safety findings in male reproductive tissues, male fertility may be impaired by treatment with IBRANCE [see PART II TOXICOLOGY, Reproductive and Developmental Toxicity]. Men should consider sperm preservation prior to beginning therapy with IBRANCE. Because of the potential for genotoxicity, male patients with female partners of childbearing potential should use adequate contraceptive methods during therapy and for at least 97 days after completing therapy.

Special Populations:

Pregnant Women: There are no adequate and well-controlled studies using IBRANCE in pregnant women.

IBRANCE may cause fetal harm when administered to a pregnant woman. In animal studies, palbociclib was shown to be fetotoxic in pregnant rats and rabbits [see PART II TOXICOLOGY].

IBRANCE should not be used during pregnancy. If IBRANCE is used in women of childbearing potential, advise the patient to avoid becoming pregnant with the use of adequate contraceptive methods during therapy and for at least 21 days after completing therapy. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Nursing Women: It is not known whether palbociclib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from IBRANCE, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the patient.

Pediatrics (< 18 years of age): The safety and efficacy of IBRANCE in children and adolescents <18 years have not been studied.

Geriatrics (≥ 65 years of age): Population pharmacokinetic analysis was performed on data from 183 patients with cancer in an age range from 22 to 89 years.  There was no clinically important difference in palbociclib exposure in patients ≥65 years of age compared with patients <65 years of age.  In IBRANCE plus letrozole-treated patients, anemia was reported more frequently in patients ≥65 years of age than in those <65 years of age, whereas similar incidences were reported in both age groups in patients treated with IBRANCE plus fulvestrant.

Hepatic Impairment: The pharmacokinetics of palbociclib has been studied in subjects with hepatic impairment. No dose adjustment is required for patients with mild or moderate hepatic impairment (Child-Pugh classes A and B). The recommended dose of IBRANCE for patients with severe hepatic impairment (Child-Pugh class C) is 75 mg once daily on Schedule 3/1 [see DOSAGE AND ADMINISTRATION and ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics]. There are no efficacy and safety data available for IBRANCE in breast cancer patients with hepatic impairment. Monitor patients for signs of toxicity.

Renal Impairment: The pharmacokinetics of palbociclib has been studied in subjects with renal impairment. No dose adjustments are required for patients with mild, moderate, or severe renal impairment. The pharmacokinetics of palbociclib have not been studied in patients requiring hemodialysis [see DOSAGE AND ADMINISTRATION and ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics]. There are no efficacy and safety data available for IBRANCE in breast cancer patients with renal impairment.

Monitoring and Laboratory Tests

Patients treated with IBRANCE should be monitored for signs and symptoms of myelosuppression and infection. Dose modification may be required [see DOSAGE AND ADMINISTRATION].

Monitor complete blood count prior to starting IBRANCE therapy and at the beginning of each cycle, as well as on Day 15 of the first two cycles, and as clinically indicated.

For patients who experience Grade 3 neutropenia, consider repeating complete blood count monitoring one week later. For patients who develop Grade 3 or 4 neutropenia, refer to the dose modification tables [see DOSAGE AND ADMINISTRATION].

Adverse Reactions

Adverse Drug Reaction Overview

The safety of IBRANCE has been assessed in 2 randomized studies of patients with HR-positive, HER2-negative locally advanced or metastatic breast.

The most common adverse drug reactions of any grade reported in ≥10% of patients receiving palbociclib in combination with endocrine treatment were neutropenia, leukopenia, infections, fatigue, nausea, anemia, stomatitis, thrombocytopenia, diarrhea, alopecia, vomiting, decreased appetite, and rash.

Most patients treated with IBRANCE (palbociclib) experienced myelosuppressive effects with over half experiencing Grade 3 neutropenia at some point during treatment. Thrombocytopenia and anemia were less commonly observed. Myelosuppressive effects can be expected to occur from Cycle 1 forward.

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

The adverse reactions are listed by system organ class, frequency category and grade of severity. Frequency categories are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).

IBRANCE plus Letrozole for the initial endocrine-based therapy of patients with ER‑positive, HER2‑negative locally advanced or metastatic breast cancer (PALOMA-2)

The safety of IBRANCE (125 mg/day) plus letrozole (2.5 mg/day) versus placebo plus letrozole was evaluated in PALOMA-2  The data described below reflect exposure to IBRANCE in 444 out of 666 patients with ER‑positive, HER2‑negative advanced breast cancer who received at least 1 dose of IBRANCE plus letrozole in PALOMA-2. Patients were randomized 2:1 to receive the combination IBRANCE plus letrozole versus placebo plus letrozole. The median duration of treatment for IBRANCE plus letrozole was 19.8 months while the median duration of treatment for placebo plus letrozole arm was 13.8 months.

Dose reductions due to an adverse reaction of any grade occurred in 36% of patients receiving IBRANCE plus letrozole. No dose reduction was allowed for letrozole in PALOMA-2.

Permanent treatment discontinuation associated with an adverse reaction occurred in 43 of 444 (10%) patients receiving IBRANCE plus letrozole and in 13 of 222 (6%) patients receiving placebo plus letrozole. Adverse reactions leading to permanent discontinuation for patients receiving IBRANCE plus letrozole included neutropenia (1%) and alanine aminotransferase increase (0.7%).

The most common adverse reactions (≥10%) of any grade reported in patients in the IBRANCE plus letrozole arm by descending frequency were neutropenia, infections, leukopenia, fatigue, nausea, alopecia, stomatitis, diarrhea, anemia, rash, asthenia, thrombocytopenia, vomiting, decreased appetite, dry skin, pyrexia, and dysgeusia.

The most frequently reported serious adverse reactions (≥1%) in patients receiving IBRANCE plus letrozole were Infections (20%) and Febrile neutropenia (2%).

Adverse reactions (≥5%) reported in patients who received IBRANCE plus letrozole or placebo plus letrozole in PALOMA-2 are listed in Table 1.

Table 1. Adverse Reactions Reported (With a Frequency of ≥5% on the IBRANCE plus letrozole arm) in PALOMA-2
 IBRANCE plus Letrozole
(N=444)

Placebo plus Letrozole
(N=222)

Adverse Reaction

All
Grades
%

Grade 3
%

Grade 4
%

All
Grades

%

Grade 3
%

Grade 4
%

Grading according to CTCAE 4.0.
CTCAE=Common Terminology Criteria for Adverse Events; N=number of patients; N/A=not applicable;
a
Neutropenia includes: Neutropenia and Neutrophil count decreased
b
Leukopenia includes: Leukopenia and White blood cell count decreased
c
Anemia includes: Anaemia, Haematocrit decreased and Haemoglobin decreased
d
Thrombocytopenia includes: Platelet count decreased and Thrombocytopenia
e
Stomatitis includes: aphthous stomatitis, cheilitis, glossitis, glossodynia, mouth ulceration, mucosal inflammation, oral pain, oral discomfort, oropharyngeal pain, and stomatitis.
f
Infections includes all reported preferred terms (PTs) that are part of the System Organ Class Infections and infestations.
g
Most common infections (>1%) are: nasopharyngitis, upper respiratory tract infection, urinary tract infection, oral herpes, sinusitis, rhinitis, bronchitis, influenza, pneumonia, gastroenteritis, conjunctivitis, herpes zoster, pharyngitis, cellulitis, cystitis, lower respiratory tract infection, tooth infection, gingivitis, skin infection, gastroenteritis viral, respiratory tract infection, respiratory tract infection viral, and folliculitis.
h
Rash includes the following PTs: rash, rash maculo-papular, rash pruritic, rash erythematous, rash papular, dermatitis, dermatitis acneiform, and toxic skin eruption.

Blood and lymphatic system disorders

Neutropeniaa

80

56

10

6

1

1

Leukopeniab

39

24

1

2

0

0

Anemiac

24

5

<1

9

2

0

Thrombocytopeniad

16

1

<1

1

0

0

Eye Disorders

lacrimation increased

6

0

0

1

0

0

Gastrointestinal disorders

Stomatitise

30

1

0

14

0

0

Nausea

35

<1

0

26

2

0

Diarrhea

26101910

Vomiting

16101710

General disorders and administration site conditions

Fatigue

37

2

0

28

1

0

Asthenia

17201200

Pyrexia

1200900

Infections and infestations

Infectionsf, g

60

6

1

42

3

0

Investigations

Alanine aminotransferase increased

10

2

<1

4

0

0

Aspartate aminotransferase increased

1030510

Metabolism and nutrition disorders

Decreased appetite

15

1

0

9

0

0

Nervous system disorders

Dysgeusia

1000500

Respiratory, thoracic and mediastinal disorders

Epistaxis

900600

Skin and subcutaneous tissue disorders

Alopecia

33N/AN/A16N/A

N/A

Rashh

18101210

Dry skin

12

0

0

6

0

0

Less Common Clinical Trial Adverse Reactions

Additional adverse reactions occurring at an overall incidence of <5% of patients receiving Ibrance plus letrozole in PALOMA-2 included dry eye (4.1%), vision blurred (3.6%), and febrile neutropenia (2.5%).

Abnormal Hematologic and Clinical Chemistry Findings

Table 2. Laboratory Test Abnormalities in PALOMA-2
 

IBRANCE plus Letrozole

(N=444)

Placebo plus Letrozole

(N=222)

Laboratory Test Abnormality

All Grades

%

Grade 3

%

Grade 4

%

All Grades

%

Grade 3

%

Grade 4

%

N=number of patients; WBC=white blood cells.

WBC decreased

97

35

1

25

1

0

Neutrophils decreased

95

56

12

20

1

1

Anemia

78

6

0

42

2

0

Platelets decreased

63

1

1

14

0

0

Aspartate aminotransferase increased

52

3

0

34

1

0

Alanine aminotransferase increased

43

2

<1

30

0

0

IBRANCE plus fulvestrant for the treatment of patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer whose disease progressed after prior endocrine therapy (PALOMA-3)

The safety of IBRANCE (125 mg/day) plus fulvestrant (500 mg) versus placebo plus fulvestrant was evaluated in a randomized, controlled, Phase 3 trial (PALOMA-3). The data described below reflect exposure to IBRANCE in 345 out of 517 patients with HR-positive, HER2-negative metastatic breast cancer who received at least 1 dose of IBRANCE in PALOMA-3. Patients were randomized 2:1 to receive the combination IBRANCE plus fulvestrant versus placebo plus fulvestrant.

The most common adverse reactions (≥10%) of any grade reported in patients in the IBRANCE plus fulvestrant arm were neutropenia, leukopenia, infections, fatigue, nausea, anemia, stomatitis, headache, diarrhea, thrombocytopenia, constipation, vomiting, alopecia, rash, decreased appetite, and pyrexia.

The most frequently reported serious adverse reactions in patients receiving IBRANCE plus fulvestrant were infections (3%), pyrexia (1%), neutropenia (1%), and pulmonary embolism (1%).

Adverse reactions reported in patients who received IBRANCE plus fulvestrant or placebo plus fulvestrant in PALOMA-3 are listed in Table 3.

Discontinuation and dose reduction due to AEs

Dose reductions due to an adverse reaction of any grade occurred in 36% of patients receiving IBRANCE plus fulvestrant. No dose reduction was allowed for fulvestrant in PALOMA-3.

Permanent discontinuation associated with an adverse reaction occurred in 19 of 345 (6%) patients receiving IBRANCE plus fulvestrant, and in 6 of 172 (3%) patients receiving placebo plus fulvestrant. Adverse reactions leading to permanent discontinuation for those patients receiving IBRANCE plus fulvestrant included fatigue (0.6%), infections (0.6%), and thrombocytopenia (0.6%).

Treatment-emergent adverse events presented in Table 3 below are based on a median duration of treatment of approximately 5 months for patients on the IBRANCE plus fulvestrant arm, and approximately 4 months for patients on the placebo plus fulvestrant arm.

Table 3. Adverse Events* Reported (With a Frequency of ≥5% on the IBRANCE Arm) for Patients Who Received IBRANCE Plus Fulvestrant or Placebo Plus Fulvestrant in PALOMA-3
*
Adverse events reported with a frequency of ≥5% on the IBRANCE arm and a higher frequency on the IBRANCE arm compared to the placebo arm
Grading according to CTCAE 4.0.
CTCAE=Common Terminology Criteria for Adverse Events; N=number of patients; N/A=not applicable.
a
Neutropenia includes: neutropenia and neutrophil count decreased
b
Leukopenia includes: leukopenia and white blood cell count decreased
c
Anemia includes: anaemia, haemoglobin decreased, and hematocrit decreased
d
Thrombocytopenia includes: thrombocytopenia and platelet count decreased
e
Stomatitis includes: aphthous stomatitis, cheilitis, glossitis, glossodynia, mouth ulceration, mucosal inflammation, oral pain, oropharyngeal discomfort, oropharyngeal pain, stomatitis.
f
Infections includes any reported PTs that are part of the System Organ Class Infections and infestations.
g
Rash includes: rash, rash maculo-papular, rash pruritic, rash erythematous, rash papular, dermatitis, dermatitis acneiform, and toxic skin eruption.

Adverse Reaction

IBRANCE plus Fulvestrant

(N=345)

Placebo plus Fulvestrant

(N=172)

All Grades

Grade 3

Grade 4

All Grades

Grade 3

Grade 4

%

%

%

%

%

%

Blood and lymphatic system disorders

Neutropeniaa

79

53

9

4

0

<1

Leukopeniab

46

25

<1

4

0

1

Anemiac

26

3

0

10

2

0

Thrombocytopeniad

19

2

<1

0

0

0

Gastrointestinal disorders

Nausea

29

0

0

26

<1

0

Stomatitise

25

<1

0

11

0

0

Diarrhea

19

0

0

17

<1

0

Constipation

17

0

0

14

0

0

Vomiting

15

<1

0

12

<1

0

Abdominal Pain

6

<1

0

5

0

0

General disorders and administration site conditions

Fatigue

38

2

0

27

1

0

Asthenia

7

0

0

5

1

0

Pyrexia

9

<1

0

4

0

0

Oedema peripheral

8

0

0

5

0

0

Infections and infestations

Infectionsf

34

1

<1

24

2

0

Metabolism and nutrition disorders

Decreased appetite

13

<1

0

8

0

0

Nervous system disorders

Headache

21

<1

0

17

0

0

Dysgeusia

6

0

0

2

0

0

Dizziness

11

<1

0

9

0

0

Psychiatric disorders

Insomnia

11

<1

0

7

0

0

Respiratory, thoracic and mediastinal disorders

Epistaxis

6

0

0

1

0

0

Cough

13

0

0

11

0

0

Dyspnoea

7

0

0

4

0

0

Skin and subcutaneous tissue disorders

Alopecia

15

N/A

N/A

6

N/A

N/A

Rashg

14

<1

0

5

0

0

SOC Investigations

Aspartate aminotransferase increased

6

2

0

5

1

0

Less Common Clinical Trial Adverse Reactions

Additional adverse reactions occurring at an overall incidence of <5% of patients receiving IBRANCE plus fulvestrant in Study PALOMA-3 included dry skin (4.9%), Vision blurred (4.9%), alanine aminotransferase increased (4.6%), lacrimation increased (4.3%), dry eye (2.9%), and febrile neutropenia (0.6%).

Abnormal Hematologic and Clinical Chemistry Findings

Table 4. Incidence of Hematology Laboratory Abnormality for Patients Who Received IBRANCE Plus Fulvestrant or Placebo Plus Fulvestrant in PALOMA-3

 

IBRANCE + Fulvestrant (N=345)

Placebo Plus Fulvestrant (N=172)

Laboratory Abnormality

All Grades

Grade 3

Grade 4

All Grades

Grade 3

Grade 4

 

%

%

%

%

%

%

White blood cells decreased

98

40

1

22

0

<1

Neutrophils decreased

95

53

9

11

0

1

Anemia

76

3

0

36

2

0

Platelets decreased

57

2

1

8

0

0

N=number of subjects.

Updated safety data of for patients on the IBRANCE plus fulvestrant arm, based on an approximate 6-month increase in the median duration of treatment, were generally consistent with the safety table provided in Tables 3 and 4. No new safety concerns have been identified.

Drug Interactions

Overview

Palbociclib is a substrate and weak inhibitor of CYP3A. It is also a moderate substrate of P-glycoprotein (P-gp) in vitro. Drug interactions were observed when IBRANCE (palbociclib) was coadministered with a strong CYP3A inhibitor and a strong CYP3A inducer. The aqueous solubility of palbociclib is pH-dependent. Drug interaction was observed when IBRANCE was coadministered with proton pump inhibitors (PPIs) under fasted conditions but was limited when IBRANCE was coadministered with PPIs under fed conditions. Food intake reduced the variability of palbociclib exposure. In vitro, palbociclib is not an inhibitor of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, and 2D6, and is not an inducer of CYP1A2, 2B6, 2C8, and 3A4 at clinically relevant concentrations.

Drug-Drug Interactions

Agents that may increase palbociclib plasma concentrations

CYP3A Inhibitors: Data from a study in 12 healthy subjects indicate that coadministration of multiple 200 mg daily doses of itraconazole with a single 125 mg IBRANCE dose increased palbociclib total exposure (area under the curve, AUCinf) and the peak exposure (Cmax) by approximately 87% and 34%, respectively, relative to a single 125-mg IBRANCE dose given alone. The concomitant use of strong CYP3A inhibitors including, but are not limited to: clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole, and grapefruit or grapefruit juice, should be avoided.

Agents that may decrease palbociclib plasma concentrations

CYP3A Inducers: Data from a study in 14 healthy subjects indicated that coadministration of multiple 600 mg doses of rifampin, a strong CYP3A inducer, with a single 125 mg IBRANCE dose decreased palbociclib AUCinf and Cmax by 85% and 70%, respectively, relative to a single 125 mg IBRANCE dose given alone. The concomitant use of strong CYP3A inducers including, but not limited to: carbamazepine, enzalutamide, phenytoin, rifampin, and St. John’s wort, should be avoided.

Data from a drug interaction study in healthy subjects (N=14) indicated that coadministration of multiple 400 mg daily doses of modafinil, a moderate CYP3A inducer, with a single 125 mg IBRANCE dose decreased palbociclib AUCinf and Cmax by 32% and 11%, respectively, relative to a single 125 mg IBRANCE dose given alone.  If concomitant use of IBRANCE with moderate CYP3A inducers (e.g., bosentan, efavirenz, etravirine, modafinil, and nafcillin) cannot be avoided, no dosing adjustments are required for IBRANCE.

Antacids: Data from a study in healthy subjects indicated that coadministration of a single 125 mg dose of IBRANCE with multiple doses of the proton pump inhibitor (PPI) rabeprazole under fed conditions decreased palbociclib Cmax by 41%, but had limited impact on AUCinf (13% decrease) compared with a single dose of IBRANCE administered alone. Given the reduced effect on gastric pH of H2 receptor antagonists and local antacids compared to PPIs, the effect of these classes of acid reducing agents on palbociclib exposure under fed conditions is expected to be minimal.

Data from another study in healthy subjects indicated that coadministration of a single 125 mg dose of IBRANCE with multiple doses of the PPI rabeprazole under fasted conditions decreased palbociclib AUCinf and Cmax by 62% and 80%, respectively, when compared with a single dose of IBRANCE administered alone.

IBRANCE should be taken with food.

Drugs That May Have Their Plasma Concentrations Altered by Palbociclib

CYP3A Substrates: Palbociclib is a weak time-dependent inhibitor of CYP3A following daily 125 mg dosing at steady state in humans. In a study in 26 healthy subjects, coadministration of midazolam with multiple doses of IBRANCE increased the midazolam AUCinf and the Cmax values by 61% and 37%, respectively, as compared to administration of midazolam alone.

The dose of the sensitive CYP3A substrate with a narrow therapeutic index (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus and tacrolimus) may need to be reduced as IBRANCE may increase their exposure.

Luteinizing Hormone Releasing Hormone (LHRH) Agonists
Data from a clinical study in patients with breast cancer showed that there was no clinically relevant drug interaction between palbociclib and goserelin when the 2 drugs were coadministered. Drug drug interaction studies between palbociclib and other LHRH agonists have not been performed.

In vitro studies with transporters
In vitro evaluations indicated that palbociclib has a low potential to inhibit the activities of drug transporters P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporter (OAT)1, OAT3, organic cation transporter transporter (OCT)1, OCT2, organic anion transporting polypeptide (OATP)1B1, and OATP1B3 at clinically relevant concentrations.

In vitro studies demonstrate that palbociclib is not a substrate of OATP1B1 or OATP1B3.

Drug-Food Interactions
Grapefruit, grapefruit juice, and products containing grapefruit extract may increase palbociclib plasma concentrations and should be avoided.

The effect of food on palbociclib exposure was evaluated in healthy subjects. Compared to IBRANCE given under overnight fasted conditions, the AUCinf and Cmax of palbociclib increased by 21% and 38% when given with high-fat food, by 12% and 27% when given with low-fat food, and by 13% and 24% when moderate-fat food was given 1 hour before and 2 hours after IBRANCE dosing. In addition, food intake significantly reduced the inter-subject and intra-subject variability of palbociclib exposure. Based on these results, IBRANCE should be taken with food.

Drug-Herb Interactions
Interactions with herbal products have not been established. St. John’s wort (Hypericum perforatum) is an inducer of CYP3A4/5 that may decrease palbociclib plasma concentrations and should be avoided.

Drug-Laboratory Interactions
Interactions between IBRANCE and laboratory tests have not been studied.

Drug-Lifestyle Interactions
Interactions between IBRANCE and lifestyle have not been studied.

Dosage And Administration

Dosing Considerations
Pre/perimenopausal women treated with the combination IBRANCE plus fulvestrant therapy should be treated with luteinizing hormone releasing hormone (LHRH) agonists according to local clinical practice.

Recommended Dose and Dosage Adjustment
The recommended dose of IBRANCE (palbociclib) is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.

IBRANCE should be taken with food.  Patients should be advised to take their dose at approximately the same time each day.

Continue the treatment as long as the patient is deriving clinical benefit from therapy.

IBRANCE is used in combination with letrozole or fulvestrant. For full dosing instructions of letrozole or fulvestrant, please consult the corresponding Product Monographs.

Management of some adverse reactions may require temporary dose interruptions/delays and/or dose reductions, or permanent discontinuation of IBRANCE as per dose reduction schedules provided in Table 5, 6 and 7.

Table 5. IBRANCE Recommended Dose Modification for Adverse Events
*
If further dose reduction below 75 mg/day is required, discontinue palbociclib treatment.

Dose Level

Dose

Recommended starting dose

125 mg/day

First dose reduction

100 mg/day

Second dose reduction

75 mg/day*

Table 6. Dose Modification and Management – Hematologic Toxicitiesa

Monitor complete blood counts prior to the start of IBRANCE therapy and at the beginning of each cycle, as well as on Day 15 of the first 2 cycles, and as clinically indicated.
 

For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles, monitor complete blood counts for subsequent cycles, prior to the beginning of every third cycle, and as clinically indicated.

CTCAE Grade

Dose Modifications

Grading according to CTCAE 4.0
CTCAE=Common Terminology Criteria for Adverse Events; LLN=lower limit of normal.
a
Table applies to all hematologic adverse reactions except lymphopenia (unless associated with clinical events, e.g., opportunistic infections).
b
Absolute neutrophil count (ANC): Grade 1: ANC < LLN - 1500/mm3; Grade 2: ANC 1000 - <1500/mm3; Grade 3: ANC 500 - <1000/mm3; Grade 4: ANC <500/mm3.

Grade 1 or 2

No dose adjustment is required.

Grade 3

Day 1 of cycle:

Withhold IBRANCE, repeat complete blood count monitoring within 1 week. When recovered to Grade ≤2, start the next cycle at the same dose.
 

Day 15 of first 2 cycles:

If Grade 3 on Day 15, continue IBRANCE at current dose to complete cycle and repeat complete blood count on Day 22.

If Grade 4 on Day 22, see Grade 4 dose modification guidelines below.
 

Consider dose reduction in cases of prolonged (>1 week) recovery from Grade 3 neutropenia or recurrent Grade 3 neutropenia on Day 1 of subsequent cycles.

Grade 3 neutropeniab with fever ≥38.5 ºC and/or infection

At any time:

Withhold IBRANCE until recovery to Grade ≤2.

Resume at the next lower dose.

Grade 4

At any time:

Withhold IBRANCE until recovery to Grade ≤2.

Resume at the next lower dose.

Table 7. IBRANCE Dose Modification and Management – Non-Hematologic Toxicities
Grading according to CTCAE 4.0
CTCAE=Common Terminology Criteria for Adverse Events. b.

CTCAE Grade

Dose Modifications

Grade 1 or 2

No dose adjustment is required.

Grade ≥3 non-hematologic toxicity (if persisting despite medical treatment)

Withhold until symptoms resolve to:

  • Grade ≤1;
  • Grade ≤2 (if not considered a safety risk for the patient)

Resume at the next reduced dose level.

No dose adjustments are required on the basis of age, gender, or body weight [see Special Populations].

Missed Dose
If the patient vomits or misses a dose, an additional dose should not be taken that day. The next prescribed dose should be taken at the usual time. IBRANCE capsules should be swallowed whole (do not chew, crush or open them prior to swallowing). No capsule should be ingested if it is broken, cracked, or otherwise not intact.

Special populations

Hepatic impairment: No dose adjustments is required for patients with mild or moderate hepatic impairment (Child-Pugh classes A and B). For patients with severe hepatic impairment (Child-Pugh class C), the recommended dose of IBRANCE is 75 mg once daily on Schedule 3/1 [see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics].

Renal impairment: No dose adjustment is required for patients with mild, moderate or severe renal impairment (creatinine clearance [CrCl] ≥15 mL/min). There are no data available in patients requiring hemodialysis [see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics].

Overdosage

There is no known antidote for IBRANCE (palbociclib). The treatment of overdose of IBRANCE should consist of general supportive measures.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Action And Clinical Pharmacology

Mechanism of Action
Palbociclib is a selective, reversible, small molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Cyclin D and CDK4/6 are downstream of multiple signaling pathways which lead to cellular proliferation. Through inhibition of cyclin D-CDK4/6 complex activity, palbociclib inhibits the phosphorylation of retinoblastoma (Rb) protein, blocking cell cycle progression from G1 into S phase. In a panel of molecularly profiled breast cancer cell lines, palbociclib exhibited the greatest efficacy towards the luminal ER-positive subtype; particularly, in cell lines with increased Rb and cyclin D1 and decreased p16 gene expression. In combination with anti-estrogen agents, palbociclib demonstrated enhanced inhibition of cell proliferation and induction of cell senescence in ER-positive breast cancer models.

Pharmacodynamics

Cardiac Electrophysiology

The effect of palbociclib in combination with letrozole on the QT interval corrected for heart rate (QTc) was evaluated using time-matched electrocardiograms (ECGs) evaluating the change from baseline at 5 timepoints during the dosing interval at steady-state in 77 patients with breast cancer.  The exposure/response analysis showed a slight positive linear relationship between QTcF and palbociclib concentration, with a mean QTcF increase of 4.14 msec at the mean steady-state palbociclib Cmax, and an upper bound of the 1-sided 95% CI <7 msec.  No patients had a post-baseline absolute mean maximum QTcF ≥480 msec or an increase from QTcF time-matched baseline value ≥60 msec during the QTc assessment period. The proportions of patients with observed changes from baseline in QTc parameters between 30 and 60 msec were comparable between the palbociclib plus letrozole and placebo plus letrozole arms.  These data suggested that palbociclib, at the recommended dosing regimen of 125 mg daily, when added to letrozole, had no large effect on QTc (>20 msec). 

Pharmacokinetics

The pharmacokinetics of palbociclib were characterized in patients with solid tumors including advanced breast cancer and in healthy subjects. Pharmacokinetic parameters of palbociclib and letrozole obtained from study A5481003 are shown in Table 8.

Table 8 Summary of Plasma Pharmacokinetic Parameters of Palbociclib (125 mg QD) and Letrozole (2.5 mg QD) at Steady State When Administered Alone or in Combination to Patients with Advanced Breast Cancer in the Phase 1 Portion of A5481003

Palbociclib PK Parameter Summary Statisticsa

Treatment

Cmax

(ng/mL)

AUC(0-24)

(ng.hr/mL)

Tmax

(hr)

t½

(hr)

CL/F (L/hr)

VzF (L)

AUC(0-24)=area under the plasma concentration-time curve from time 0 to 24 hours after dosing;
CL/F=apparent oral clearance; Cmax=maximum observed plasma concentration; CSR=Clinical Study Report;
%CV=percent coefficient of variation; LTZ=letrozole; N=total number of patients in the treatment arm;
PK=pharmacokinetic; PLB=Palbociclib; QD=once daily; Std Dev=standard deviation; Tmax=time to first occurrence of Cmax;
t1/2=terminal plasma half-life; Vz/F=apparent volume of distribution.
a. Geometric mean (geometric %CV) is shown for all PK parameters except median (range) for Tmax and arithmetic mean (±Std Dev) for t1/2.

PLB alone (N=12)

PLB + LTZ (N=12)

116 (28)

108 (29)

1982 (29)

1933 (31)

7.9 (2.2-8.2)

7.9 (2.0-8.1)

28.8 (±5.0)

-

63.1 (29)

-

2583 (26)

-

Letrozole PK Parameter Summary Statisticsa

LTZ alone (N=12)

LTZ + PLB (N=12)

104 (31)

95.0 (27)

1936 (35)

1739 (30)

1.0 (0-4.4)

2.0 (0.8-4.1)

-

-

-

-

-

-

Absorption: Following oral single-dose administration, palbociclib was absorbed with median time to achieve Cmax of 4 to 8 hours. The mean absolute bioavailability of IBRANCE after an oral 125 mg dose is 46%. In the dosing range of 25 mg to 225 mg, the AUC and Cmax increased proportionally with dose in general. Steady state was achieved within 8 days following repeated once daily dosing. With repeated once daily administration, palbociclib accumulated with a median accumulation ratio of 2.4 (range 1.5-4.2).

Food effect: The effect of food on palbociclib exposure was evaluated in healthy subjects. Compared to IBRANCE given under overnight fasted conditions, AUCinf and Cmax of palbociclib increased by 21% and 38% when given with high-fat food, by 12% and 27% when given with low-fat food, and by 13% and 24% when moderate-fat food was given 1 hour before and 2 hours after IBRANCE dosing. In addition, food intake significantly reduced the inter-subject and intra-subject variability of palbociclib exposure. Based on these results, IBRANCE should be taken with food.

Proton pump inhibitors effect:
In a healthy subject study, coadministration of a single dose of IBRANCE with the PPI rabeprazole under fed conditions decreased palbociclib Cmax by 41%, but had limited impact on AUCinf (13% decrease), when compared to a single dose of IBRANCE administered alone.

In another healthy subject study, coadministration of a single dose of IBRANCE with the PPI rabeprazole under fasted conditions decreased palbociclib AUCinf and Cmax by 62% and 80%, respectively, when compared to a single dose of IBRANCE administered alone.

Distribution: Binding of palbociclib to human plasma proteins in vitro was ~85%, with no concentration dependence over the concentration range of 500 ng/mL to 5000 ng/mL. The mean fraction of unbound (fu) palbociclib in human plasma in vivo increased with worsening hepatic function. There was no obvious trend in the mean palbociclib fu in human plasma in vivo with worsening renal function. The geometric mean apparent volume of distribution (Vz/F) was 2583 L.

Metabolism: In vitro and in vivo studies indicated that palbociclib undergoes hepatic metabolism in humans. Following oral administration of a single 125 mg dose of [14C]palbociclib to humans, the major primary metabolic pathways for palbociclib involved oxidation and sulfonation, with acylation and glucuronidation contributing as minor pathways. Palbociclib was the major circulating drug-derived entity in plasma (23% of total radioactivity in plasma). The major circulating metabolite was a glucuronide conjugate of palbociclib (14.8% of total radioactivity in plasma), although it only represented 1.5% of the administered dose in the excreta. In feces, the sulfamic acid conjugate of palbociclib was the major drug-related component, accounting for 25.8% of the administered dose. In vitro studies with human hepatocytes, liver cytosolic and S9 fractions, and recombinant sulfotransferase (SULT) enzymes indicated that CYP3A and SULT2A1 are mainly involved in the metabolism of palbociclib.

Excretion: The geometric mean apparent oral clearance (CL/F) of palbociclib was 63.08 L/hr, and the mean plasma elimination half-life was 28.8 hours in patients with advanced breast cancer. In 6 healthy male subjects given a single oral dose of [14C]palbociclib, a median of 91.6% of the total administered radioactive dose was recovered in 15 days; feces (74.1% of dose) was the major route of excretion, with 17.5% of the dose recovered in urine. The majority of the material was excreted as metabolites. Excretion of unchanged palbociclib in feces and urine was 2.3% and 6.9% of the administered dose, respectively.

Special Populations and Conditions:

Age, Gender, and Body Weight

Based on a population pharmacokinetic analysis in 183 patients with cancer (50 male and 133 female patients, age range from 22 to 89 years, and body weight range from 37.9 to 123 kg), sex had no effect on the exposure of palbociclib, and neither age nor body weight had a clinically important effect on the exposure of palbociclib.

Pediatric Use

Pharmacokinetics of palbociclib have not been evaluated in children and adolescents <18 years of age.

Hepatic Impairment

A pharmacokinetic trial was conducted in subjects with varying degrees of hepatic function who were administered a single 75 mg dose of palbociclib. In this study, palbociclib unbound exposure (unbound AUCinf) decreased by 17% in subjects with mild hepatic impairment (Child-Pugh class A), and increased by 34% and 77% in subjects with moderate (Child-Pugh class B) and severe (Child-Pugh class C) hepatic impairment, respectively, relative to subjects with normal hepatic function. Peak palbociclib unbound exposure (unbound Cmax) was increased by 7%, 38% and 72% for mild, moderate and severe hepatic impairment, respectively, relative to subjects with normal hepatic function. In addition, based on a population pharmacokinetic analysis that included 183 patients with advanced cancer where 40 patients had mild hepatic impairment based on National Cancer institute (NCI) classification (total bilirubin ≤Upper Limit of normal (ULN) and Aspartate Aminotransferase (AST) >ULN, or total bilirubin >1.0 to 1.5 × ULN and any AST), mild hepatic impairment had no effect on the pharmacokinetics (PK) of palbociclib.

Renal Impairment

A pharmacokinetic trial was conducted in subjects with varying degrees of renal function who were administered a single 125 mg dose of palbociclib. In this study, total palbociclib exposure (AUCinf) was increased by 39%, 42%, and 31% with mild (60 mL/min≤CrCl<90 mL/min), moderate (30 mL/min≤CrCl<60 mL/min), and severe (CrCl <30 mL/min) renal impairment, respectively, relative to subjects with normal (CrCl ≥90mL/min) renal function. Peak palbociclib exposure (Cmax) was increased by 17%, 12%, and 15% for mild, moderate, and severe renal impairment, respectively, relative to subjects with normal renal function. In addition, based on a population pharmacokinetic analysis that included 183 patients with advanced cancer where 73 patients had mild renal impairment and 29 patients had moderate renal impairment, mild and moderate renal impairment had no effect on the PK of palbociclib. The pharmacokinetics of palbociclib have not been studied in patients requiring hemodialysis.

Japanese population

Data from a pharmacology study evaluating the effect of Japanese ethnicity on the PK of a single 125-mg oral palbociclib dose given to Japanese and non-Asian healthy volunteers indicate that palbociclib AUCinf and Cmax values were 30% and 35% higher, respectively, in Japanese subjects when compared with non-Asian subjects.

Storage And Stability

Store at 20oC to 25oC; excursions permitted between 15oC to 30oC.

Special Handling Instructions

Any unused product or waste material should be disposed in accordance with local requirements.

Dosage Forms, Composition And Packaging

IBRANCE (palbociclib) is supplied in the following strengths and package configurations:

IBRANCE Capsules

Package Configuration

Capsule Strength (mg)

Capsule Description

Bottles of 21 capsules

125

opaque, hard gelatin capsules, size 0, with caramel cap and body, printed with white ink “Pfizer” on the cap, “PBC 125” on the body

Bottles of 21 capsules

100

opaque, hard gelatin capsules, size 1, with caramel cap and light orange body, printed with white ink “Pfizer” on the cap, “PBC 100” on the body

Bottles of 21 capsules

75

opaque, hard gelatin capsules, size 2, with light orange cap and body, printed with white ink “Pfizer” on the cap, “PBC 75” on the body

List of excipients

Microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and hard gelatin capsule shells. The light orange, light orange/caramel and caramel opaque capsule shells contain gelatin, red iron oxide, yellow iron oxide, and titanium dioxide; and the printing ink contains shellac, titanium dioxide, ammonium hydroxide, propylene glycol and simethicone.

 

Control #: 207909
June 5, 2018

Contact Pfizer Medical Information

Report an Adverse Event
1 866 723-7111